Developmental funds have been used for two purposes during the last grant cycle and we propose to continue funding in these areas in the next grant cycle. 1) Pilot Funds - The CCSG developmental funds support three types of pilot grants, each targeting a different Cancer Center member group: ? Push grants - to accelerate (or """"""""push"""""""") the pace of effort on cancer-focused research initiatives judged to have a high potential to lead to peer-reviewed funding within 1 -2 years. Pull grants - to encourage cancer research among non-cancer members and new members, i.e. to """"""""puir them into the Cancer Center. Paff/7er grants - to encourage clinicians to partner with a basic or population scientist in a joint project in translational research. Partner grants require matching funds from the clinical department. These pilot grants have yielded a return of investment of about 14 fold over the past five years. We plan to continue using these pilot project mechanisms in the next grant cycle. 2) Shared Resource Development - We have used CCSG developmental funds from the past grant cycle to support our Crystallography and Computational Biosciences (CCB) shared resource. This shared resource was originally proposed in our last competing renewal and is now requested as a full shared resource. In the new grant cycle, we propose funding for two developing shared resources: Synthetic Chemistry and Translational Imaging. In addition to continuing funding for these two areas, we propose adding bridge funding support in the next grant cycle.

Public Health Relevance

Developmental funds provide a key source of support for the strategic and programmatic priorities and scientific opportunities of our Center as identified through our planning and evaluation processes. These funds provide the opportunity to explore innovative pilot projects, new collaborations and new technologies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA012197-39
Application #
8617231
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
39
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Yang, M; Forbes, M E; Bitting, R L et al. (2018) Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? Ann Oncol 29:311-323
Godwin, Ryan C; Gmeiner, William H; Salsbury Jr, Freddie R (2018) All-atom molecular dynamics comparison of disease-associated zinc fingers. J Biomol Struct Dyn 36:2581-2594
Votanopoulos, Konstantinos Ioannis; Bartlett, David; Moran, Brendan et al. (2018) PCI is Not Predictive of Survival After Complete CRS/HIPEC in Peritoneal Dissemination from High-Grade Appendiceal Primaries. Ann Surg Oncol 25:674-678
Lamar, Zanetta S; Dothard, Andrew; Kennedy, LeAnne et al. (2018) Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. Leuk Lymphoma 59:1871-1877
Melvin, Ryan L; Xiao, Jiajie; Berenhaut, Kenneth S et al. (2018) Using correlated motions to determine sufficient sampling times for molecular dynamics. Phys Rev E 98:023307
Bhatt, Nikunj B; Pandya, Darpan N; Dezarn, William A et al. (2018) Practical Guidelines for Cerenkov Luminescence Imaging with Clinically Relevant Isotopes. Methods Mol Biol 1790:197-208
Gesell, Sabina B; Golden, Shannon L; Limkakeng Jr, Alexander T et al. (2018) Implementation of the HEART Pathway: Using the Consolidated Framework for Implementation Research. Crit Pathw Cardiol 17:191-200
Mao, Chengqiong; Qu, Ping; Miley, Michael J et al. (2018) P-glycoprotein targeted photodynamic therapy of chemoresistant tumors using recombinant Fab fragment conjugates. Biomater Sci 6:3063-3074
Bhatt, Nikunj B; Pandya, Darpan N; Rideout-Danner, Stephanie et al. (2018) A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant 89Zr-immuno-PET agents. Dalton Trans 47:13214-13221
Andrews, Rachel N; Caudell, David L; Metheny-Barlow, Linda J et al. (2018) Fibronectin Produced by Cerebral Endothelial and Vascular Smooth Muscle Cells Contributes to Perivascular Extracellular Matrix in Late-Delayed Radiation-Induced Brain Injury. Radiat Res 190:361-373

Showing the most recent 10 out of 548 publications